SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-21-025844
Filing Date
2021-05-12
Accepted
2021-05-12 17:21:52
Documents
59
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0321_aditxtherapeutics.htm 10-Q 358420
2 CERTIFICATION f10q0321ex31-1_aditxtherap.htm EX-31.1 10116
3 CERTIFICATION f10q0321ex31-2_aditxtherap.htm EX-31.2 10168
4 CERTIFICATION f10q0321ex31-3_aditxtherap.htm EX-31.3 10111
5 CERTIFICATION f10q0321ex32-1_aditxtherap.htm EX-32.1 5755
  Complete submission text file 0001213900-21-025844.txt   2849330

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE adtx-20210331.xml EX-101.INS 325738
7 XBRL SCHEMA FILE adtx-20210331.xsd EX-101.SCH 48739
8 XBRL CALCULATION FILE adtx-20210331_cal.xml EX-101.CAL 29828
9 XBRL DEFINITION FILE adtx-20210331_def.xml EX-101.DEF 204341
10 XBRL LABEL FILE adtx-20210331_lab.xml EX-101.LAB 407570
11 XBRL PRESENTATION FILE adtx-20210331_pre.xml EX-101.PRE 213435
Mailing Address 2569 WYANDOTTE, ST. SUITE 101 MOUNTAIN CA 94043
Business Address 2569 WYANDOTTE, ST. SUITE 101 MOUNTAIN CA 94043 909-488-0844
Aditx Therapeutics, Inc. (Filer) CIK: 0001726711 (see all company filings)

IRS No.: 823204328 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39336 | Film No.: 21916246
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences